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Introduction
Studying Trial Communities: 
Anthropological and Historical 
Inquiries into Ethos, Politics and
Economy of Medical Research 
in Africa 
P. Wenzel Geissler
Overseas Medical Research
This book is about medical research carried out in Africa, by African in-
stitutions and their collaborators from Europe and the USA. It is thus about
what used to be called ‘overseas’ medical research, a term which – unlike
more recent terms such as ‘transnational’ or ‘collaborative’ – recalls its im-
perial origins as well as the assymetrical topography of power and resources
it still involves. Overseas research is shaped by its geographical and politi-
cal-economic frames, as well as by colonial history and by the process of
nation building, and decay, that marked the postcolonial era (or, as Om-
bongi, below, distinguishes, the ‘postcolonial’ and the ‘post-postcolonial’).
This is why the authors of this volume, participants of the conference
‘Studying Trial Communities’, held in 2005 at the Kenyan Medical Research
Institute (KEMRI) Centre for Geographical Medicine in Kilifi, Kenya, in-
clude historians among the majority of anthropologists, and why many of
the anthropologists here draw upon historiography or historical sources
for the purpose of their ethnography. Medical research in Africa is an area
intensely shaped by history, and the fact that it often is oblivious to its own
origins and genesis makes it particularly important that we combine ethno-
graphic and historical-archaeological investigations.
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The chapters below focus on contemporary medical research endeavours
and, to a lesser extent, their postcolonial prehistory. They cover a range of
African countries, and diverse types of medical research: clinical studies, drug
development and randomised controlled trials, entomological surveys and
vector control, ethnobotany and phytopharmacology, even medical anthro-
pology. What they have in common is a commitment to understanding how
medical research is shaped in the interactions — set within stark political and
economic disparities — between global scientists and their institutions, na-
tional and transnational forms of government, and people who contribute
time and effort, and often also bodily substance, to research projects, either as
temporary employed staff, or as study subjects without direct, formal remu-
neration. The contributors ask why, and under which circumstances, scientific
medical work takes on particular forms, and how the people and institutions
involved determine what is right and wrong, and which direction to take. Un-
derlying these inquiries is, for many of the authors, the question of how
scientific investigations – as well as the public good that medical science makes
possible – could be realised in a more democratic and equitable manner. Thus,
their scholarly occupation with science in Africa is intertwined with reflections
on the politics and ethics of medicine, in the ‘overseas’ situation of unequal sci-
entific and technical capacity and great disparities in power and wealth. 
The Ethos of Medical Science
This book could be said to be about the ethics of research, but it does not
limit itself to the domain of discourse that recently has been cast as ‘research
ethics’ or ‘bioethics’ in the regulatory sense of guidelines and principles of
‘good clinical practice’ (see e.g. CIOMS 2002), and which has given rise to
some fruitful debate in public health and attendant social sciences. This lit-
erature blossomed in particular during the past decade, stimulated, among
other sources, by the human rights discourse that evolved around HIV/AIDS,
and, more specifically, by the debates provoked by the 1997 discussion among
scientists and ethicists on appropriate ‘standards of care’ in African HIV re-
search (see Angell 1997; Lurie and Wolf 1997). Simplifying a rich debate for
the purpose of positioning this volume, we can discern a continuum across
this literature, ranging from contributions that aim to produce better regu-
latory frameworks or to implement rules more systematically (e.g. Leach et
al. 1999; Emanuel et al. 2004), to social research that enriches the debate
through the use of sociological and anthropological method (e.g. Molyneux
et al. 2004, 2005a,b; Fairhead et al. 2006; Parker et al. 2008). 
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The authors of the latter kind of texts often critique and qualify the terms
set out in standard bioethics guidelines, or resituate research ethics in their
political-economic context – thereby critiquing their inherent ‘anti-political’
effects (e.g. Benatar and Singer 2000). By contrast, the former – social sci-
ence that remains within the delineations of the existing bioethics discourse
– tends to reify these limitations of regulatory bioethics, excluding, at times
explicitly, questions of political and economic inequality and interest from
the purview of ethical ‘worries’ (see Emanuel et al. 2005). The contribution
of this literature to critical debate about medical research and scientific
knowledge, and thus to the creation of egalitarian and democratic science,
is therefore limited by an implicit acceptance of the status quo. Setting them-
selves in particular apart from this normative version of the scholarly debate
on medical research ethics, the anthropologist or historians below situate
themselves outside the frames of existing normative ‘bioethics’, and many
critique these frames or their epistemological and political premises (see
e.g. Dilger, Heald, Strathern, White). In as far as they do directly refer to re-
search ethics, they prise open the taken for granted closures of existing
ethical discourses, in order to create the possibility of thinking up alterna-
tives. In other words, the chapters collected in this volume wish to extend the
critical and analytic end of the spectrum delineated above.1
While most contributors below acknowledge the importance of legal in-
struments to regulate medical research, the ethical impulse behind their
chapters is different from that which drives bioethics guidlines in the sense
embodied by ‘Good Clinical Practice’.2 For the sake of distinguishing it from
‘ethics’ in the restricted sense that is now often taken for granted in the con-
text of medical research – emphasising the protection of individual rights at
the expense of a wider societal project including the pursuit of justice – one
could refer to this different concern as the ‘ethos’ of medical research, that is,
the visions and projects that orientate and direct the discourses and practices
of different actors and groups, in different places, situations and periods.3
Ethos in Time 
Scientific ethos, or articulations of ethos in relation to medical science, is
shaped by historical and political-economic circumstances, and revealed
by close attention to how different actors, in different localities and times,
produce scientific evidence in particular ways, how they express motiva-
tions and aims, take decisions, identify and solve problems, chose ways
forward and evaluate past actions. Ethos can be articulated on diverse 
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levels of scale – including, for example, commitment to thoroughness and
pride in technical inventiveness, faith in progress and enlightenment, com-
mitment to freedom, welfare, equality or democracy – and linked to
different wider societal projects – such as the nation or a global common-
wealth, the market or the welfare-state. In contrast to narrow definitions of
‘ethics’ in terms of guidelines and rules, the broader study of ethos empha-
sises the problem of direction over that of particular choice, the openness
of intention and anticipation over the closure of a right or wrong action.
Asking for the ethos of science is searching for the projects implied in it, the
imagined futures and pasts, and thus it is as much about temporality as it
is about morality (for the centrality of time for diverse articulations of
ethos, see also Badiou 2002).
Articulations of ethos shift over time, and not infrequently the broad
frames of one historically situated ethos serve as shared ground, upon
which struggles about diverging interest can be carried out. A key example
of this, which several of the chapters below attend to (e.g. Ombongi, Schu-
maker, Geissler), is the specifically modern, mid-twentieth century ethos
which took modernisation, progress and development for granted, and
which shaped science and drew upon it to expound visions of society and
government. The outlines of this particular ethos may be particularly vis-
ible to us, today, for two reasons. It has been analysed, critiqued and
deconstructed, most fruitfully by the Frankfurt School and later by the Fou-
cauldian tradition, giving us a sense of distance from it; and yet, as we
inhabit an increasingly uncomfortable and destructive sort of after-moder-
nity, we cannot help but rediscover some of the attractiveness of the
outdated hopes of our modern forebears (whom we now know have never
been modern, leaving us with a task at hand). 
Importantly, this modern ethos served also in the African medical con-
text as a shared frame of reference for politically and economically radically
opposed interests: colonial medical administrators could draw upon it to
justify, for example, racial segregation, while anti-colonial freedom fight-
ers could demand medical equality and redistribution of the fruits of
progress. Claims and counter claims could thus be made with reference to
this one overarching ethos. Choices could be contested, even fought over,
within this frame, which did not provide simple moral answers. This po-
tential inclusiveness, and ambivalence of ethos, which allows for diverging
interests, conflict and dialectics, is an important difference to ‘ethics’ as
conceived of in regulatory research ethics.
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Ethos and Politics
In a similar way, a contemporary ethos based on individual freedom and
rights and the value of life can be drawn upon to defend very different in-
terests, for example those of the pharmaceutical industry claiming
intellectual property rights, and those of treatment action campaigns de-
manding equal rights in HIV treatment; those of industry-sponsored
‘patient advocacy’ groups demanding high-cost drugs for unproven im-
provements of patients’ lives, and those of ‘right to die’ activists, who oppose
the dictate of life-extending medicinal technology (see Ong and Collier
2005). Thus, within the space of an overarching ethos different interests
can be both disputed and brought together. Indeed, as most of the authors
below will agree, contestation, consensus-making and contradictions are
inevitable dimensions of the historical process, and must be named and ar-
ticulated in the political engagement of science. At the same time, different
articulations of ethos can coexist, compete and interrelate within one his-
torical situation. For example, in the field of medical science and healthcare,
individual rights provide for a very different ethos from that of older gov-
ernment public health; yet, both coexist around many of today’s key health
issues. If we, for example, want to engage with the ethical challenges that
HIV research and intervention pose, we need to understand how these dif-
ferent kinds of ethos overlap, mix and conflict across this field; we must
consider the different political and societal projects entailed by, respec-
tively, emphasising individual rights to confidentiality and voluntariness, or
the responsibility of government public health to minimise suffering and
maximise citizen’s welfare.
Commitments in the sense of ethos thus go beyond rule-set ‘ethics prin-
ciples’. The latter distinguish right and wrong, an inside and an outside,
divided by a moral line. Such an apparently clear moral separation obscures
the more ambiguous political and economic struggles that shape medical
science, and the society that it exists in and brings about. Discussions about
the ‘ethos’ of science include interest and conflict into the purview of eth-
ical reflection rather than excluding them by the sanitising morality of
principles. Ethical action can thus be anchored again from where it has
been unmoored: if science is about truth and value – with all the term’s
moral-cum-economic ambiguity (see e.g. Kelly and Geissler 2011) – these
are inseparable from power and resources. Whether science harbours the
possibility of change – the improvement of knowledge, lives and societal
order – depends crucially upon whether and how the linkages between
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ethics, epistemology and political economy are rendered visible, negoti-
ated and contested. Struggles about ethos are thus linked to questions of
truth as well as to matters of interest. 
Trial Communities
Anthropologists are usually called to work on medical research with a clear
remit: to study ‘the community’, that is what medical research protocols de-
fine as ‘study populations’ and ‘participants’ or ‘volunteers’. Their task is,
then, to describe certain characteristics of this group, such as ‘prepared-
ness’ and ‘response’ to a clinical trial, or ‘cultural’ concepts and behaviours
of significance to the trial or intervention. The aim of the anthropologists
assembled in this volume, and their historian colleagues, is different. Their
unit of analysis is, in diverse ways, not a particular, delimited group, but
sections of a wider network that is constituted not through attachment to
a place or ‘culture’, but by the work of collaborative medical research.4
When we met at the conference in Kilifi, Kenya, whence this book de-
rives, we referred to this network of actors engaged in medical research –
for some of us including non-human actants – as the ‘trial community’.
This definition of the subject has two implications: it opens the frame to in-
clude everyone concerned, and it shifts focus from the concerns arising
from a particular social grouping to those arising from the relations be-
tween points, nodes and groups in the network. This allows discerning new
collectives and solidarities – such as trial volunteers, data collectors and
entry clerks and other workers in scientific production sites – and new con-
nections, distinctions and separations, for example between Zambian and
US American doctors, or between medical anthropologists and medical
ethics. Finally, a focus on the production of  associations destabilizes taken
for granted boundaries – such as the line between ‘community’ and ‘re-
searcher’, the difference between ‘cultures’, between scientific and traditional
medicine and so on.5
Since we met in Kilifi in 2005 to study ‘trial communities’, which we then
felt were an exciting, largely unexplored field, several important works have
been published, which in diverse ways apply anthropological knowledge
to overseas medical research, if not all of them in Africa, and which inspire
many of the authors below in their ongoing work (e.g. Biehl 2005; Nguyen
2005; Petersen and Folayan 2005; Petryna 2006, 2009; Rajan 2006; Cooper
2008). The fact that these important books speak a somewhat different lan-
guage from that of many of the authors below is not only due to the editor’s
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tardiness (most chapters were written before these works became available
to the authors) but also due to slightly different starting points. Most of
these recent publications on clinical research aim to shift the location of
anthropology to levels of scale that explode the notion of locality, as dis-
cussed previously, for example by Gupta and Ferguson (1997); they take a
principal interest in what Ong and Collier described as ‘global assemblages’
(2005), working through the global construction, and transformation, of
scientific production. The contributors to this volume come at similar is-
sues and concerns from a slightly different angle, one perhaps grounded
more in the empirical, ethnographic British-European tradition of social
anthropology, starting out from concrete social realities – which not only,
but also and importantly, consist of concrete, localised social engagements
and experiences.
Moreover, these recently published works share an interest in the polit-
ical economy of overseas research – which is what makes them so inspiring
against the backdrop of less clearly political forms of medical anthropology
and ethics. Partly therefore, they focus mostly on commercial, industry-
driven transnational medical research or on the effects of private, capital
interest in bioscience (e.g. Petryna 2005, 2009; Rajan 2006 Cooper 2008),
and most of them take a particular interest in clinical trials – as the most
advanced and industry-endorsed form of medical research – and less in
the wider field of public health research. The papers in this volume do not
pursue such a coherent agenda. In the open spirit of the Kilifi meeting, they
are more diverse and eclectic, exploring different possibilities of making
medical research and medical knowledge in Africa the centre of anthro-
pological attention. Moreover, many of the authors below focus their
interest mostly on medical research in the public domain, funded by gov-
ernment or bilateral arrangements and conducted by government or
parastatal organisations. Although publicly funded and governed medical
and public health research is of course increasingly affected by ‘partner-
ships’ with private enterprise and charity, and by reformulations of
academic intellectual property rights in the wider neoliberal context, pub-
lic scientific institutions and the research they conduct pose slightly
different challenges from the (important) critique of commercial, openly
profit-oriented research, and might also help us to discern diverse direc-
tions and intentionalities in the conduct of science today, as well as discover
alternatives to the neoliberalisation of science that Cooper (2008) and oth-
ers have successfully explored. 
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Critical Ethnographies 
Underneath the diversity of geographical areas, scientific domains and his-
torical periods, and different political viewpoints and disciplines, the papers
assembled here share a commitment to ethnography in the sense of trac-
ing relations and separations that shape social space. For most of us,
ethnography implies both studying social relations across domains and lev-
els of scale, and beyond locality, and understanding people’s, including
scientists, lives; both fascination with ‘global assemblages’ and attention to
intimate social encounters and engagements. Both are needed to question
formations and habits that have become commonsensical, to make visible
structures and processes that are obscured or ignored, and to contribute to
the critical analysis of science and society. 
Most of the texts in this book could be said to be ‘critical’ studies of med-
ical research and its ethos, in the sense not of ‘anti-science’ – all contributors
are committed to scientific medical research and progress, and none has
an issue with science as such – but of allowing us to see scientific research
in a different way, and positioning science within relationships that at times
are overlooked, at other times downplayed and ignored. 
First, attention is fixed within the material realities, both of the research
work and of the lives of people involved in research, including political and
economic inequality and deprivation. Second, authors attend to the insti-
tutional relationships beyond the purview of research itself, within given
localities such as between government healthcare system, pharmaceutical
industry and medical research – and across levels of scale, between national
government and transnational institutions and corporations. Analysing
such networks means tracing visible as well as unseen connections, and ex-
ploring the aggregations and separations produced by social, spatial and
epistemological categories. As such the critical study of medical research
aims to prise apart the pre-existing and newly formed social relations –
such as the ‘community’ that performs much work in contemporary un-
derstandings of research ethics – and to problematise separations such as
that between researchers and research participants, which projects a prob-
lematic epistemological distinction onto social space and overlays,
sometimes obscures, other social distinctions. Last but not least, contribu-
tors aim to reveal alternative solidarities, material similarities, overlapping
interests and tensions attendant to these groupings – such as, relating to
the previous example, the material similarities and overlapping interests
among overseas research participants and some categories of technical re-
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search staff, and between different groups of scientists within transnational
scientific collaborations.
In other words, the social studies collected in this volume are not posi-
tioning themselves opposite medical science, aiming to cast doubt over or
relativise its value and validity. Most contributors would indeed defend the
superiority of a scientific approach to medicine, and the achievements of its
tools, like randomised controlled trials, and its products, like antibiotics
and childhood vaccines. And neither do most of the contributors take the
side of a particular group in overseas research – such as the research par-
ticipants, or the underprivileged community – vis-à-vis the researchers and
their institutions, as certain older anthropological solidarities would call
for by default. Our aim, then, is not so much to ‘take sides’, but to make
sides: to discern contradictions and separations, bonds and cohesions, that
need to be debated in order to produce better science and better public
medicine. The overarching deontological question is: where do we want
science to take us? What futures are we aiming for through science? As
such, ‘critique’ means here a search for openings, not definite positioning
and closure (see Geissler 2011). 
Overview of the Book
The chapters below, which were discussed at the 2005 Kilifi conference, were
grouped into three sections: engagements, evidence and politics. Since all of
them deal with relations, epistemology and power, these headings serve not
so much as compartments, but as three intersecting lines of inquiry.
Engagements
The chapters of the first section took the conference theme most literally,
focusing on the relations that make up medical research, and some of them
have left a particular imprint on other, subsequent, papers in this collection.
Whyte’s exploration of a Ugandan epidemiologist’s research, and of the
role of paper in it, sets up a distinction between epistemological and onto-
logical concerns; between knowledge and acknowledgement, ‘knowing
about’ and ‘knowing’ people. Whyte pursues the relational possibilities of
scientific work by showing that paper, apart from its capacity to contain
information, can also embody substantial relations. While contrasting ob-
jectified knowledge and ‘being together’, she shows that both inhere to the
same practices and may be pursued by the same people within the same
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work; all ‘situated social actors’ are motivated by both ways of knowing and
by both capacities of the practice of writing knowledge. Thus, Whyte im-
plies, we should not attribute epistemological motives to scientists and
relational ones to study subjects. All members of trial communities learn
new abstractions and gain understandings, and all must get to know oth-
ers in the process of research work; and knowing and relating changes those
involved. In conclusion, Whyte calls for ethnographic attention to the in-
terfaces where making knowledge creates relations, and knowledge relies
upon relational practices. While this is clear advice to ethnographers of re-
search, the intertwining of knowing people and making knowledge that
Whyte describes should also have implications for scientists conducting
research: instead of the widespread tendency to exclude or silence the re-
lational dimension of knowledge-making, for example through
bureaucratic apparatuses and regulatory standards, it should be taken se-
riously, not only as a complementary foundation of ethics, but also as a
contribution to science itself.
Approaching concerns with epistemology and ontology from a different
angle, Strathern takes issue with the notion that the engagement between
researchers and researched is predicated upon divergent, respectively sci-
entific or local, ‘perspectives’ (onto one reality) that have to be aligned
through ‘information’ and ‘communication’, in order to achieve effects –
namely scientific results. Such ‘perspectivalism’ might label the ‘non-scien-
tific perspective’ as ignorance (to be corrected through information), or –
more fashionably – as local ‘cultural’ knowledge, which scientists should un-
derstand and appreciate for the sake of better communication. Despite the
different degree of political correctness in these two renderings of the ‘local’
or ‘lay perspective’, the assumption is the same: the other has a different way
of seeing; shifting perspective – in the first case ‘theirs’ in the second case
‘ours’ – is proposed as the solution. Both approaches focus on epistemol-
ogy. Instead, Strathern suggests to consider the cultural, ‘Euro-American’,
nature of perspectival knowledge itself: ‘perspectives’, and the concomitant
notion of ‘context’ (supposedly shaping perspectives) is for her not a solu-
tion to the problem of difference, but ‘part of the problem’.
To make this point, Strathern examines ethnographic cases in which en-
gagements among humans and the world are not conceived of as epistemic
exercises directed at one substantive reality, but as substantial relations pro-
ducing diverse forms of being – the dispute about ownership and belonging
of museal human remains is a case in point. Instead of knowledge and in-
formation, Strathern suggests to ‘rely on relations’, notably of bodies. The
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social relations around field research, which many of the other papers in the
book explore, are thus not peripheral, secondary – not ‘the social context
of data’ – but substantial, central to knowledge generation. As witnessed
by my summary, this argument is easily reduced to the very pattern of op-
posite ‘world-views’ that it critiques: epistemological scientists versus
ontological natives. The ethnographic labour consists in discerning the mu-
tual articulation of these modes in the practices of research; here, I think
Whyte’s material above, and many of the chapters below can be of use.
Leach and Fairhead’s exploration of ‘being with’ research in The Gambia
deals more directly with the problems of knowing and being, or rather with
the intertwining, sometimes collision, between the epistemological concerns
of scientific knowledge production and the material struggles and conflicts
of the people engaged in research. They show that the uncertain world in
which Gambians live is partly specific to local social forms and cultural un-
derstandings, as well as, in an important sense, an outcome of global
economic processes. Therefore, the balance of benefit and danger that par-
ents consider when consenting to clinical trial participation is not a matter
of free choice; larger frames of power and value are at work, and local actors
are aware of, and part of, these. Leach and Fairhead conclude that ethical
assessments of medical research must consider the context of healthcare de-
livery and health seeking, and draw our interest to the separations between
matters of health, in its social breadth and open-endedness, and matters of
life, in the sense of trial participation and mere survival; they consider how
these separations are produced and negotiated around overseas research
and its ethics (see also Molyneux et al. 2005a on this issue).
Like Leach and Fairhead, Dilger draws on the notion of context to reflect
about the methodology and ethics of his own medical-anthropological re-
search on AIDS in Tanzania. After ‘ethical clearance’ by Tanzanian
authorities, which assessed and re-shaped his study according to medical
ethics standards, he went to different field sites and found that ethics, rather
than being universal, as the medical ethics committee had assumed, are ‘con-
textual’, shaped by local ‘politics of speaking’, ‘moral constellations’ and
‘epistemologies of illness’. Dilger concludes that the ethics of medical-an-
thropological research ought to be guided less by medical ethics rules, but
by continuous reflection about the research process, including reflexion on
the fieldworker’s own position in the field. The latter point gains, he argues,
particular significance where the situation under study entails extreme
forms of suffering and loss – as in his own case of anthropological research
on AIDS. Is ethnography in such circumstances a mere ‘bourgeois luxury’
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or could it, as Dilger suggests, help to make better, in his words ‘locally
adapted’, public health interventions, or could it even help to prise open and
thus unsettle the wider structures that perpetuate the unequal distribution
of suffering? The social relations that are the foundation of his ethnographic
knowledge also ought to be the basis of his ethical commitment.
Manton’s historical inquiry moves us into an age before ‘research ethics’
– although we can sense strong and not always aligned modes of ethos at
work in his historical study of pharmacological research by mission hospi-
tals, nationalist governments and travelling scientists and global companies
in mid-century Nigeria. He examines relations and transitions across global
inter-personal and institutional networks, in view of tracing different in-
terests that went into a new drug, as well as of charting relations between
local ‘field research’ and global realms of science and experimentation.
Though his analysis operates on a less localised level than, for instance,
Whyte’s, Manton shows how universal standards are shaped by local al-
liances and shape local experience – an observation that might as well be
applied to research ethics as to, in his case, laboratory standards. He re-
veals how technical problems and tensions with people and things, and the
wide and often surprising circulation of research between local instances
and global negotiations, shape scientific outcomes, and even the disease in
question, leprosy, itself. Just as the drug on trial – a red powder which ap-
parently dispersed easily and stuck to anybody it got in touch with – the
research that went into its clinical testing, Manton shows, produced mul-
tiple relations and transformed not only bodies, but also personal and
institutional lives across continents.
We end this section with Ulrich’s reflection, as an anthropologist and
philosopher, upon the ongoing bioethics controversies, which oppose the
advocates of global bioethics regulations to those who denounce current re-
search ethics as hollowed-out versions of ethical reflection, or as external
standards enforced by central institutions in rich countries – imperialist
variations on global ‘audit cultures’. Some of these critics of formal rules
propose instead to place ethics in the realm of the private, in individual de-
cisions and morality. Ulrich shows how the latter assault against formal
bioethics tends to reiterate the individualizing and privatizing tendency in-
herent to certain current interpretations of bioethics.6 In contrast to such
privatised ethics, Ulrich insists that medical science requires ‘public ethi-
cal legitimation’. The ‘public ethics’ that he – based on Kant and on
Habermas – proposes ‘positions all social actors equally and accords an
equal say in the pursuit of judgement of what is right’. What is thus needed
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is ‘situated accountability’ (as opposed to ‘accountancy standards’): spaces
in which to account for or challenge the ethics of research. 
This renewed emphasis on ‘the public’ raises the question of where to
locate such a ‘communicative, reciprocal’ ethics in today’s collaborative
medical research settings – situations equally far removed from the dis-
cursive equality of the agora of the ancient polis, and from Habermas’ 1970s
western Germany. In the old contract of ‘public health’, medical science was
assumed to be directed, controlled and utilised by the nation-state as the le-
gitimate representation of its citizens, for the benefit and welfare of the
latter (see e.g. Titmus 1971). While this contractual relation has world-wide
been cast into doubt by the scholarly critique of biopolitics of the 1980s, as
well as by the realities of neoliberal assaults on national welfare institutions,
in Africa it has been particularly brutally severed by the gradual criminal-
isation of the state and the hollowing of its politics of representation, and
the destruction of much of its its public sector, accelerated by external eco-
nomic and political pressures. Although there certainly still is a large public
sector in many African countries – notably in health care and education,
urban administration and the legal system – its function is at least am-
biguous: both evoking projects and memories of a national collective, and
embodying its destruction and absence. The primary ethical challenge
today would thus be to circumscribe the lost ‘public’ to restore and safe-
guard the condition of a public ethics.
To further this, Ulrich proposes that anthropologists explore potential
‘sites of accountability’, ranging from national and international institutions
to interactions between groups and individuals involved in research, and
that historians trace the genesis and demise of the ‘public’, in view of restor-
ing this achievement of the Enlightenment.
The ideal of ‘public ethics’ draws our attention to the material constitu-
tion and dissolution of the public, and the demise of the nation-state and
democratic representation, and to the surge of ‘bioethics’ that has come to
fill some of the spaces vacated by the democratic public sphere. In response
to the present weak and undemocratic public discourse and to ‘forge re-
ciprocal communicative contexts’, the position of state and public academic
institutions in research  should, according to Ulrich, be reinforced, and the
‘qualified opposition with which researchers ... are met’ by people and in-
stitutions in developing countries strengthened.7
We chose to conclude this section with Ulrich’s chapter because his 
reflections serve as a valuable antidote to the misunderstanding to which
anthropologists are prone: to place our hope in ‘relations’. While these of
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course are our analytical target, they carry no moral value and the impli-
cation of immediacy, and its assumed moral value, that the term can carry,
offers no solution to the problem of the democratic and egalitarian consti-
tution of overseas medical research.8
Evidence
The book’s second section focuses on how evidence is produced and negoti-
ated in medical research. Participating in preparations for collaborative
research in Ghana and Zambia, Feierman notices different conceptions of  ‘ev-
idence’ among clinicians working, respectively, in African government and
US American university hospitals. These differences, he shows, are shaped
not by ‘culture’ but by the material conditions under which doctors can put ev-
idence into effect. Faced with the ‘normal emergency’ of government
healthcare, the African doctors look for evidence fitted to the specific prob-
lems faced by their hospitals at a given moment in time – for example how to
make clinical judgements without optimal diagnostics. Such limited, local,
make-do evidence is problematic for the US American counterparts bent on
contributing to academic research and dependent upon competitive funding.
They propose instead to link global standards and local situations by research
on ‘low-tech’ practices independent from latest technical devices and drugs,
a proposition that will be discussed also by Ombongi’s historical paper, below.
Interestingly, although Feierman does not elaborate this point, such clinical
trials of ‘adapted’, low-cost interventions must adhere to the highest med-
ical standards in order to satisfy US regulations. Thus, while the African
doctors might prefer to retain the aim of state-of-art global medicine as a
frame, while making do with local, temporary shortfalls in research prac-
tice, their American colleagues want to test localised forms of medicine
while applying global medical standards in the trial regime. The latter ap-
proach means shifting the frame of evidence, creating another kind of
universal, standardised medicine, rather than the instable, localised im-
provisations within one universal frame proposed by the African doctors.
The former approach generalizes differences in resources and capacity:
poor technologies for poor places.9 The African colleagues are not content
with this because they remain committed to aspiring towards global stan-
dards, and because they do not regard local as static. For them, the lack of
capacity in their hospitals constitutes not a given, but a ‘not yet’, or a ‘no
longer’, with respect to the scope of medical science and the mandate of a
national teaching hospital. Research on low-tech medicine means for them
relinquishing the ideal of global universal science.10
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Feierman concludes that African doctors – negotiating scientific aspi-
ration, clinical practice and daily economic survival – should be critical
mediators of collaborative research. This raises the question of who sets
the research agenda as one of the ethical cum political-economic dimen-
sions of collaboration that requires anthropological scrutiny. The demand,
by doctors working in Africa, of medical research that inserts itself into
their world, can be linked to the call for ‘pragmatic’ clinical trials that is
elaborated in the subsequent chapters by Kachur and Kelly. If a large-scale
trial is tailored to local technological and administrative conditions, like in
Kachur’s case, is this what Feierman’s doctors have in mind when they call
for local evidence?
Kachur’s chapter deals also with two different conceptions of evidence
around a US government research project in Tanzania: ‘experimental’, based
on randomised controlled trials (RCT), which shows how well a technology
works under ideal conditions, and ‘observational’ or ‘quasi-experimental’,
which shows how things would work under ‘real world’ conditions.11 Within
this contrast, RCTs could be said to imply transcendence by pointing at what
could be done in the absence of mere political or economic constraints; ob-
servational studies remain, somewhat akin to the low-tech medicine critiqued
by Feierman’s African doctors, immanent to the existing societal situation:
they show what can be done within given political and economic conditions.12
Kachur describes a quasi-experiment to study drug resistance, delivery ef-
ficacy and cost involving an approved anti-malarial drug. The Tanzanian
Ministry of Health agreed with the US public health organisation to intro-
duce the new drug ‘as a matter of local policy’ rather than as a clinical trial.13
Thus, ‘national and local authorities have taken responsibility’ and the ex-
periment does not need ‘individual informed consent’, nor specific
information about the drug on trial. Yet, while the researchers overall main-
tain a ‘low profile’, they ‘alter or enhance’ some aspects of the delivery system
to ascertain the validity – dependent upon regular drug delivery – and the
ethical and legal correctness – relying upon monitoring of adverse events –
of the experiment.14 This raises, as Kachur points out, the question of what
variables are to be altered, compared to ‘reality’, and which ones must re-
main stable to maintain resemblance with normality. In other words, what
is imagined as a realistic change of reality? In the given study, only the drug
is shifted (apart from improved adverse event monitoring for regulatory rea-
sons); healthcare staff levels and resources remain unchanged.15
Comparing the contrasting modes of evidence described by Feierman
and Kachur, one could be inclined to see parallels between the African cli-
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nicians’ pragmatism and the ‘pragmatic’ research design. Both are more
‘localised’ and specific than, respectively, clinical trials of innovative low-
tech interventions and the RCT, which address more generalisable levels
of evidence. Yet, on another level one could argue that the clinicians’ local
experimentation and the RCT share a commitment to the open-ended po-
tentiality of science, while both low-tech and pragmatic trials share a
commitment to ‘reality’ as represented by the status quo. As Kachur un-
derlines, observational studies look for ‘real world outcomes’, not for results
that reveal the potential capacity of science; similarly, low-tech interven-
tions purposely aim below not beyond the limits of known science, to
remain within the seemingly insurmountable limits of the ‘real’.16
Kelly’s chapter expands on the question of how ‘reality’ is constructed
when it is modelled in trials. It also relates to Feierman’s concern with how
evidence is constituted in different contexts of healthcare delivery. Again,
the relationship, shaped by the political economy, between means and ends,
and between evidence and ethics in clinical research is in focus. Two trials
run by the Medical Research Council in Britain and The Gambia evoke
both ‘pragmatic’ entanglements between everyday life and scientific evi-
dence: scientific representations and medical realities converge in a
co-productive process, albeit within two very different systems of health-
care. While the UK healthcare standards are, apart from the tested
intervention, equivalent to those of the experimental context, in The Gam-
bia, the by-and-large absence of public medical care separates the realities
of research and care provision. Indeed, the distance between medical real-
ities and trial regime is so large that participants consider the experiment
a ‘healthcare system’ (see also Leach and Fairhead), and, maybe partly in re-
sponse to this wide gap, the Gambian study sets itself apart as an RCT, not
attempting to be ‘pragmatic’. However, as Kelly’s ethnography shows, the
purity of the RCT is modified in manifold ways to accommodate the local
situation, which is why Kelly recommends a greater dose of explicit ‘prag-
matism’, akin to the UK pragmatic trial, testing simultaneously new
technologies and modes of delivery, addressing questions of causality and
effect and matters of political economy. 
Kelly’s chapter opens up the larger question of how ‘clinical researchers are
to adopt a pragmatic position’. Engagements between science and everyday life
are uncertain, and it is precisely this enduring uncertainty, incompleteness
and openness that make science epistemologically as well as socially genera-
tive. Can a ‘pragmatic trial’ foster this surprising potential of the scientific
endeavour? It might as well simply prove what is known already, thus ce-
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menting ‘security’ (in Peirce’s sense of the term, opposed to the productiveness
of ‘uncertainty’), which, while practically important, curbs the creative possi-
bility of science. Is it possible to build in pragmatic or ‘real world’ elements
into existing forms of clinical research, irrespective of its wider political-eco-
nomic situation? If it is done, what happens to the notion of reality? Is there
not a subtle difference between engaging science in (unpredictable) social and
political processes, allowing for transformations of either or both, and insert-
ing (some selected) social elements into a scientific trial regime? 
Feierman’s African scholars point towards a possible alternative to the
accommodation of human unpredictability into trial regimes: unlike prag-
matic anti-malarial trials or low-tech interventions trials, their approach
is fundamentally pragmatic in that it maintains the ‘subjunctive’, trying
mode of clinical engagement and pragmatic science (see Whyte 1997). Par-
aphrasing Peirce (quoted by Kelly): their ideas have life, generative life. The
fact that it is exactly this approach to scientific inquiry that is not easily
turned into large-scale collaborative trials, and cannot command funding
streams – unlike pragmatic trials, quasi experiments and the like – might
be indicative of this peculiar ‘insecured’ quality. How exactly to promote
such a pragmatic science – which is not necessarily a simpler, lower vari-
ety of high science – remains an open question for the social study of
science. Part of the answer might, again, lie in the wider public to anchor
healthcare, public health and medical research (see Ulrich). If experimen-
tation were to be part of a continuous and effective process of government,
and constituted within systems of both democratic representation and con-
trol, the hiatus between science and reality might become less dramatic. 
Mueller-Rockstroh’s chapter on Dutch ultrasound machines in Tanzania
links the problem of shifting contexts of evidence to ethics by asking how
‘good’ scientific knowledge is produced. Relating pregnant women’s, doc-
tors’ and administrators’ understandings and uses of ultrasound, she
suggests that rather than asking what is ‘good technology’, we should at-
tend to its varied effects in different situations – intended and unintended,
beneficial to some and harmful to others. The ethical question what ‘good’
technology may be is thus turned into a matter of negotiation: ‘good-ness
is a choice between different worlds’; and diverse goods call forth different
interests. This supports empirically Ulrich’s conclusion that ethics is, and
indeed should be, a matter of contest, and that the validity of ethical judge-
ment depends upon transparent and balanced modalities of arbitration.
In an aside, Rockstroh suggests another small but important distinction:
that between ‘good’ and ‘better’. While ethics discussions often understand
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the notion of ‘social good’ as analogous to ‘value’, there is an important dif-
ference between the good of a technology – the value for society or a
particular group – and the prospect of betterment, ‘hope for the better’ –
embodied by a technology. Rockstroh’s ethnography draws our attention
to that latter, subjunctive and directional quality, which is not necessarily
identical with the actual effects intended or achieved by science and tech-
nology, but which nevertheless can make people utilise technology, pursue
science and change their reality.
The last three chapters in this section share a more direct interest in the
political context of evidence. Langwick’s chapter on government traditional
medicine research in Tanzania underlines, again, that scientific proof
emerges in the details of research methodologies and the structures of re-
search institutions and collaborations, and that the conditions that allow
some things to be proven and not others change over time. Her work sheds
light in particular on the changes that occurred between the 1970s and
today, a period during which Tanzania has taken a particularly radical turn
from social democracy to radical privatization and ‘re-structuring’. For tra-
ditional medicine this implied, as Langwick shows elsewhere, a shift from
herbs as resources for national health to herbs as possibilities in the glob-
alised economy (see Langwick 2001).
Langwick shows how values and practices that bolster particular forms
of proof – in other words traditional medicine which is elaborated through
scientific study – are sedimented in institutional structures. In her case, so-
cial studies and pharmacological and botanical studies relate in a specific
way: the former covering largely what is deemed ‘unnecessary’ and ‘un-
captured’ by the latter. As a result of this order of knowing traditional
medicine, Langwick shows, healers and their rituals are variously included
or excluded from the development of traditional medicine. This effect of
epistemological and institutional structures raises methodological, politi-
cal and ethical questions, and opens the possibility of renegotiating the
integration of traditional medicine and biomedicine.
Geissler’s chapter on ageing Kenyan government scientists’ memories of
a bygone era of nation-state public health covers a similar period as Lang-
wick’s work – 1960s to the present – looking back from the post-neoliberal
era to distant, long-lost modern times. Exploring the lives of scientific
workers, the chapter discerns a particular notion of evidence linked to di-
rect action on concrete public health problems. This notion of ‘field-work’
relied upon the integration of scientific work into the frames of the nation-
state and a – however fragile and at times violent – contractual relationship
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between citizen and government. This modern project claimed that it is
possible to understand the world, and that it can be changed. This faith in
two kinds of interdependent transformation – of knowledge and of what
has been made known – permeated the men’s biographies. Their lives as
quintessentially modern government scientists underline the necessity to
think epistemological and political economic questions jointly, and they
cast some doubt over certain anthropological and historiographic views of
the state and medicine, current in the 1990s, that viewed the state as an en-
tity vis-à-vis its people and focused analysis on its controlling and
disciplining nature. Instead of the spatial imaginaries of the people as op-
posed to the state (or that of science juxtaposed to its subjects), which often
underlies scholarly and ethical reflections on government and science, the
men’s lived-in ethos of truth and transformation points to the importance
of temporality to understand health science, not merely as governmental
domination and discipline, but as a project.
Heald’s chapter closes this section with a somewhat related reflection on
‘public health’ versus the current rights-based, ‘exceptionalist’ approach to
HIV in Kuria, Kenya, an area heavily affected by AIDS. Heald links the ex-
ceptional status of HIV/AIDS among other, comparable health problems to
its early association with certain rights-based interest groups, and to the
fact that its outbreak coincided with the beginning of the global human
rights wave that paralleled political-economic neoliberalisation. Opposi-
tion to such HIV exceptionalism has been raised by public health policy
makers (e.g. Bayer 1991). Heald finds similar arguments in her Kuria in-
formants’ commentary upon bioethical regulations around HIV research
and intervention, and specifically their apparent opposition to confiden-
tiality and voluntariness, which they argue contributes to the spread of HIV,
and their calls for obligatory testing and publication of test results. In con-
clusion, Heald considers the idea that some of the ethical constraints of
VCT might be counterproductive, and that HIV research and intervention
should reconsider the emphasis on individual autonomy, rights and choice
– making for an interesting convergence between anthropological and pub-
lic health perspectives.
While there of course are diverse opinions on the issue of confidentiality
and patient rights among public health scientists and western Kenyans, the
point made by Heald and the informants she quotes points back to the public
health contract that the old scientific workers in Geissler’s chapter remembered
from 1960s health science. The old men’s longings for authoritative, even au-
thoritarian, and effective public health knowledge, and some Kuria people’s
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rejection of liberal and individualised approaches to HIV, seem to express a
yearning for public health interventions in the interest of a wider social collec-
tive, for the (re)constitution of some sort of a ‘public’ in relation to public health.
Importantly, there seems to be at present no shortcut to such larger whole, as
any nostalgic attempt to return to 1960s postcolonial nation-state health would
be as futile as politically dubious. Indeed, in the situation of criminal or failing
states, a call for authoritarian public health policies would be dangerous, and
probably detrimental to health. Thus, rather than siding with the different calls
for a ‘return’ to public health that emerges in the last two chapters, anthropol-
ogists and historians ought to reflect about what happened to the ‘public’ that
once held together government and citizens in one collective, which pursued
– or at least claimed to do so – betterment and welfare. The next step would
then be to decide what kind of collectives we might want to (re?)create to face
the current epidemiological and political-economic situation.
Politics
Accordingly, the book’s last section brings together chapters that occupy them-
selves with politics and the history of medical research and public health.
Ombongi opens the section with an analysis of the shifting relation be-
tween state and biomedical policy in the colonial, postcolonial and what
he calls ‘post-postcolonial’, or post-1980s era. While he stresses that colo-
nial public health was a dimension of colonial hegemony and social control,
and that science served also ‘the legitimisation of cultural superiority’, he
also acknowledges that biomedicine was part of an (albeit paternalistic)
state modernisation process. This modernist project fed then, in the 1960s
and 1970s, into a progressive nationalist research agenda, expanding pub-
lic health infrastructure and research institutions during the postcolonial
era. Only by the late 1970s did it become evident that the government had
become unable to deliver on its medical and scientific promise, and con-
sequently the state lost prominence as an agenda-setting actor in public
health and medical research. In its stead, new para-statal, non-state and in-
ternational institutions were created while the bodies of government health
science and public health decayed. Ombongi’s chapter provides us thus with
a broad periodisation that can be generalised – and fruitfully compared –
to other African countries. In so doing, he draws our attention, as histori-
ans and anthropologists, to the as yet largely under-researched period of the
long 1980s, the era of the liberalisation of science and health, which calls for
new analytic modes and approaches compared to the history of colonial
medicine and research.
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The following chapter by Lachenal takes on this task. Looking at the life of the
Institut Pasteur in post-independence Cameroon, Lachenal works out a specif-
ically French ethos of  ‘collaboration’, which emphasises the aim to assimilate
the postcolonial subject –‘Cameroonisation’ – while continuously postponing
the actual transition of power and authority. The short-lived nationalisation of
the Institute Pasteur in 1975 reveals the difficulties that the loss of French re-
sources and contacts entailed at a time of economic crisis and neoliberal
globalisation; nationalisation appears as a noble but doomed anachronism in
the face of the political and economic restructuring of the nation and of sci-
ence. Attending to the ideologies of separation supporting the continuous
‘collaboration’, Lachenal examines work arrangements and relations among
staff, and traces the ‘moralisation’ of professional categories, and the cultural-
isation of politics, framed by old racist stereotypes. The colonial order is
thereby, he argues, perpetuated and transformed within the new global polit-
ical arrangement. Lachenal’s conclusion is characteristically ambivalent: while
he does consider that global ethical standards could provide an opportunity
to critique and address inequalities in research collaboration, he also notes
with chagrin that such standardisation will entail the loss of the specifically
French ethos of cooperation which, in spite of its obvious imperfections, arose
in on-going face–to-face relations and thus offered possibilities of negotiation,
contestation and change, which are not easily captured by formalised ethics.
Schumaker’s chapter takes us back in time, to corporate malaria research
and control in a colonial Northern Rhodesian copper mine. Scientists’ and
industry representatives’ views of malaria control were here linked to the
control of workers in a contested economic terrain. Miners and local
malaria control workers, while often resisting this project, nevertheless as-
sociated scientific work with modernity’s universal promise of progress and
wellbeing. Colonial antagonism did not preclude the emergence of a mod-
ernising dream that united, underneath racial repression and
proto-nationalist resistance, the colonial occupants and their workers. This
joint ‘research culture’ of malaria control made ‘different people and inter-
ests work together on a common project despite their often radically
different understandings of the project’s meaning’. Schumaker’s study re-
veals the double-edged nature of modern (medical) science, noted above:
disciplining in the context of existing power–knowledge alignments, on
the one hand, and yet, on the other, opening horizons for hope and for
transformation, which ultimately may move beyond existing arrangements. 
Speculating about the future rather than looking into the colonial past,
Nguyen’s chapter follows Schumaker’s interest in medical charity and aid by
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discussing the impact of global flows of antiretroviral medicines (ARV), pro-
duced by US American and European companies and procured by US
government and transnational charities, to Africa. He suggests parallels be-
tween the current re-formation of medical intervention in the context of HIV
and the colonial history of medical intervention in Africa. In his view, ARV
policies challenge national sovereignty and foreshadow a renewed ‘military
therapeutic complex’, in which military might and therapeutic power, with
scientific authority, are deployed for the political ordering of the world. He
argues that what at present happens in Africa is indicative of ‘global futures
of biomedicine’ – much in the same way in which past tropical medicine was
a laboratory of colonial power and of metropolitan science – in the sense that
the production and distribution of pharmaceuticals and the maintenance of
bare life will be a key to the future order of government, and to the link be-
tween political and economic power and scientific knowledge.
Our book ends with a final chapter by Luise White, who shares Nguyen’s
concerns with ‘imperialist’ tendencies in some forms of overseas medical
research and intervention in Africa. Using the case of smallpox, she traces
a persistent disconnect between medical and health policy actions and the
interpretations and intentions of those – African bodies, societies and na-
tions – that have been subjected to these actions, over the course of the
twentieth century. She argues that in the face of this divergence between
those in power (scientifically and politically) and those whose bodies ex-
perience this power, the current utilisation of research ethics is doubtful at
least, if not harmful. The question of whether a particular procedure is ‘eth-
ical’, she states, is secondary to the question whether the whole political
and epistemological process can be judged ethical, in a broader sense of
the term. In view of powerful transnational interests in medical science
that overshadow African national sovereignty (in her view, especially those
of the USA), White insists that medical intervention and research must be
viewed not primarily as an ethical issue, but as a political contest. And she
concludes that: ‘the broader context of medical intervention [throughout
the twentieth century] … originates so far from African concerns and
African consent that it cannot be called ethical at all’, and that medical
ethics ‘simply avoids the larger question’. Provocatively running counter to
the entire research ethics debate, she insists that we should ‘not worry
whether this or that individual consented to a particular injection’ but ‘why
some injections are available and others not’, and who controls this.
It must be said that White’s historiographic head-on assault on regulatory
bioethics was not shared by all participants at the Kilifi conference. We nev-
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ertheless let her chapter close this collection, giving her the last word on the
matter, because it marks one endpoint of the spectrum of our fruitful dis-
cussions in and after Kilifi, and because we do think that the underlying
concern with radical political economic inequality, exclusion and domina-
tion is shared widely – indeed also among some of the ethicists and scientists
she critiques – and does provide an important starting point for further,
joint thinking about the ethos of medical science in Africa. It is our hope that
these conference proceedings, like the sustained dialogue that the meeting
in Kilifi has encouraged, will contribute to the open, engaged and theoreti-
cally informed debate on the ethics and political economy of medical
research in Africa and elsewhere – a discussion that is willing to include di-
versity of views, controversy and conflict, and more: a debate which accepts
that position, interest and conflict are inevitable features and driving forces
of the historical process, including the progress of medical science.
Notes
1. The papers assembled here consider themselves closely related to the latter part of
the recent bioethics literature that uses ethnographic and other forms of social in-
quiry to open up and transform the ethics debate. We have earlier published a
special issue that brought together those papers from the Kilifi conference that re-
late more closely to the ‘research ethics’ debate (Molyneux and Geissler 2008). The
reason why we decided to publish the texts separately is not their incompatibility,
but the fact that those published earlier directly insert themselves into the inter-
disciplinary bioethics debate, while those assembled below remain closer to their
specific disciplinary origins outside the medical realm.
2. ‘Good Clinical Practice’ (GCP) is a regulatory protocol, issued by the International
Conference on Harmonisation, that details practical procedures, including those
pertaining to ethical matters (consent, incentives etc.) around clinical trials. It has
been endorsed by the World Health Organisation and by the US Federal Drug Ad-
ministration, which is responsible for licensing pharmaceuticals to the world’s
largest pharmaceutical market, and it is therefore of crucial importance to the con-
duct of clinical trials all over the world, shaping widespread ideas about what the
ethics of medical research are about (see e.g. EMEA 2002). In their GCP version,
the ethical challenges of overseas research are inevitably reduced and focused on
procedural matters, as exemplified by various online GCP/ethics certificates (see
e.g. www.onlinegcp.org). It is this reduced version, rather than the important
bioethics dialogue between philosophers, religious authorities, publics and scien-
tists, that many of the authors in this volume react against.
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3. The Oxford English Dictionary defines ethos as ‘the characteristic spirit, prevalent
tone of sentiment, of a people or community; the “genius” of an institution or sys-
tem’ (although it originally has its roots in the Greek word ‘etho’ or ‘to be
accustomed to’) (Oxford English Dictionary, http://www.oed.com/viewdic-
tionaryentry/Entry/64840).
4. For an exemplary discussion of how biotechnological networks stabilise a ‘public’
see Hayden (2003).
5. The choice of trial ‘community’ was maybe, in  retrospect, unfortunate, as it echoes
the boundedness of the older ethnographic object and thus misrepresents the open-
ness of the associational webs produced by overseas research – ‘network’ would
have been a more contemporary formulation. Yet, to many of us, this old fashioned
term also evokes one of the virtues of old ethnography, as we understand it: a
methodological commitment to partake in the associational spaces that we study,
including importantly the engagement with and positioning among sets of peo-
ple, with their things and institutions, projects and memories.
6. Ulrich’s critique of this choice between pseudo-legal standards and personal moral-
ity echoes the observation, made by Harvey (2006), that neoliberalism erodes the
democratically constituted public sphere and reduces the role of state and public
institutions to legal protection of private property, leaving deontological commit-
ments to private, often religious, morality and noeconservativism.
7. Since the Kilifi conference, several initiatives have been undertaken both by re-
search institutions as well as activist groups to support the qualified engagement
of various publics with overseas collaborative medical research (see e.g. the reflec-
tions of the activist de Cenival 2008). 
8. The publication of this volume was overtaken by the second Kilifi conference on
‘The publics of public health’ (December 2009), which discussed the collectives of
bioscientific work and public health in Africa (see Kelly and MacGregor, in prepa-
ration).
9. This discussion between American and African doctors recalls Ferguson’s de-
scription of ‘telos’ and ‘status’ in relation to modernity. While the African doctors
retain the modern medical telos in spite of adversity, the ‘appropriate technology’
approach ascribes lastingly different (lower) status to African health systems (see
Ferguson 2006).
10. The quest for low-tech solutions, advocated by doctors from high-tech institutes for
the poorest people, have another problem: they tend to bypass national levels of
medical decision making, reaching out to what is designated as ‘community’. De-
cisions are made by northern scientists, on behalf of southern patients, excluding
local medical and political elites. This bypassing threatens national capacities, and
may, as Feierman’s conversations with African doctors show, exclude important
insights into the nature and use of medical evidence. It contributes to the erosion
of the public, in Ulrich’s sense, above, and of accountability and legitimacy of re-
search. This ‘bypassing’ is thus a particularly important ethical concern to be
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studied by social scientists (see also Ulrich’s observation of a Ugandan doctor’s
views of the 1997 research ethics debates).
11. This is a similar – though not identical – problematic as Feierman’s. As Kachur
points out, the latter approach tries to include a clinical perspective into its field of
vision, but this is not the same as seeing and acting like a clinical practitioner.
12. When the findings of the latter are put into practice, disappointment is less likely
than in the case of purified RCT results. On the other hand, the knowledge pro-
duced by such ‘realistic’ studies does not necessarily point beyond existing
conditions: the pure, in a sense radical, truth of RCTs evokes political-economic de-
mands; the realism or relative truth of quasi-experiments, by contrast, risks
remaining within the seemingly given conditions of global inequality. 
13. Kachur’s trial presents us with a distinctive innovation: while the destination of the
medical intervention remains the citizen’s body, the experiment pertains to the health-
care system; unit of randomisation and consent is thus not the individual but the
district. While in standard experiments the body of the experimental subject is inter-
vened into, in this case the body of the nation is modified. This policy-experimentality
has some continuities with governmental experiments throughout the twentieth cen-
tury (see e.g. Bonneuil 2000); yet, the contemporary experiments are carried out by a
sovereign nation-state in collaboration with a foreign government. While the inves-
tigators led by Kachur have carefully considered the ethical questions arising from
this new constellation, the political import of such an experimental regime would de-
serve further anthropological and historical reflection. 
14. Kachur describes the choice involved in the latter aspect: not to test every female
patient who is prescribed ACT for pregnancy, but to monitor closely those who
had inadvertently been given the drug. Since the drug had not yet been approved
in pregnancy ‘to some observers … this appeared to be inconsistent’. The evidence
resulting from the safety monitoring has an ambiguous status. While the primary
motive of monitoring the effect of the drug on pregnant women is ethical and legal
– driven by responsibility for subject health – the outcomes provide evidence of
drug safety. Thus, while pregnancy exposure to the drug must not be an experi-
ment, the effects are findings. 
15. This innovative type of trial reproduces, on an unusually large scale, the inherent ten-
sion of tropical clinical research: on the one hand, it requires that the clinical situation
is different from what might be the case in industrialised countries with well-devel-
oped healthcare systems – different epidemiological profiles and different material
conditions of care – and thus it has to be firmly situated in a particular place, such as
a clinic. On the other hand, it aspires to universal standards of validity (and ethics) and
must therefore detach itself from the place, by establishing separate, globally certified
laboratories, or by transferring scientific specimens to other places, and by providing
global standards of care. While simultaneous emplacement and detachment are reg-
ularly negotiated within African research hospital settings, in this case the scale of
emplacement/disentanglement is larger: a district, and potentially the nation.
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16. The shift, in recent years, from research proper to ‘effectiveness studies’ or ‘evalu-
ations’ that are more ‘real world’ and often less stringent in terms of controls and
regulatory concerns/ethics is, as Kachur mentions, exacerbated by the fact that
many new large-scale funders of health interventions (e.g. Pepfar) preclude the use
of their funds for research in a stricter sense, and demand at the same time con-
tinuous exercises in ‘evaluation’. This conflation of experiement and intervention,
could be said to be characteristic for contemporary African biopolitics.
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